ArticleClinical and experimental nephrology2026
A new frontier in edema management: the potential of tolvaptan for refractory edema with hyponatremia in pediatric nephrotic syndrome.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere nephrotic edema in children often necessitates use of one or more diuretics. Moderate to severe hyponatremia co-exist in such patients. Tolvaptan, a vasopressin receptor antagonist, has shown promise in treating edema in adult as well as pediatric cases, however in children there is not much data. This study aims to explore the use of tolvaptan in severe nephrotic edema with hyponatremia in children.
methodsChildren with Nephrotic syndrome (1-12 years) with severe edema were screened for eligibility and received furosemide (2-4 mg/kg/d) for 48 h, those refractory to furosemide (weight loss < 3%) with hyponatremia (Na < 130mEq/L) were administered tolvaptan (0.3-1 mg/kg/d) for 48 h after excluding hypovolaemia, elevated liver enzyme and reduced eGFR (< 60 ml/min/1.73m2). Parameters were compared before and after 48 h of tolvaptan.
resultsA total of 60 (44 males, 16 females) patients were enrolled with mean age of 5.71 ± 2.16 years. After 48 h of tolvaptan administration, there was significant reduction in body weight (21.98 ± 6.33 to 21.02 ± 6.28 p < 0.001). and increase in 24-hour urine volume from 700 (400-1060) mL/day [1.56 ± 0.91 mL/kg/hour] to 1200 (900-1637.5) mL/day [3.17 ± 2.53 mL/kg/hour] (p < 0.001). The mean serum sodium level increased significantly from 125.87 ± 3.77 mEq/L to 131.18 ± 4 mEq/L (p < 0.0001). There was no significant change in liver enzymes after tolvaptan.
conclusionsTolvaptan effectively reduces edema, increases urine output while improving serum sodium levels in pediatric nephrotic syndrome with refractory edema without any significant side effects.
Indexed as
Identifiers
42762409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.